ACUTAAS CHEMICALS LIMITED
₹4,002.65+₹21.10 (+0.5%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹13,806 Cr
- P/E
- 61.2x
- EV / EBITDA
- 154.5x
- Revenue
- ₹990 Cr
- Net margin
- 6.4%
- ROCE
- 12.3%
Price chart
Technical chartScreen technicals →+134.6% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +22.1%
- 3M
- +23.8%
- 6M
- +54.2%
- 1Y
- +134.6%
- 5Y
- +657.4%
52-week range
Day change +₹21.10 (+0.5%) from ₹3,982 to ₹4,003 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in ACUTAAS, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 23.4%
Concerns1
- Low return on equity of 6.5%
Rule-based from financial data. Not advice.
About the company
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson's, antidepressant, and anticoagulant applications.
Read moreShow less
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson's, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist chemicals to semiconductor applications; electrolyte additives for lithium battery cells; and parabens, methyl salicylate, and other commodity chemicals for cosmetics, agrochemicals, and fine chemicals. The company was formerly known as Ami Organics Limited and changed its name to Acutaas Chemicals Limited in May 2025. Acutaas Chemicals Limited was founded in 2004 and is based in Surat, India.
- Sector
- Healthcare
- Shares outstanding
- 8.2 Cr shares
- ISIN
- INE00FF01025
- BSE code
- 543349
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹13,806 Cr
- P/E
- 61.2x
- P/B
- 9.7x
- EV / EBITDA
- 154.5x
- EV / Sales
- 20.2x
- P/S
- 20.1x
- Earnings yield
- 1.6%
- 52-week high
- ₹4,002.65
- 52-week low
- ₹1,552.25
Profitability
- Operating margin
- 15.7%
- Net margin
- 6.4%
- EBITDA margin
- 13.1%
- ROE
- 6.5%
- ROCE
- 12.3%
- ROA
- 4.1%
- Dividend payout
- 25.0%
- Tax rate
- 37.0%
- Other income, % of PBT
- -26.1%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹990 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 43.9%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 23.4%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹90.0 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -29.1%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 263.6%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.3%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹101 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 80.4%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹155 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 41.1%
Solvency and efficiency
- Current ratio
- 3.05
- Debt / Equity
- 0.30
- Debt / Assets
- 0.19
- Debt / EBITDA
- 2.26
- Interest coverage
- 18.00
- Financial leverage
- 1.59
- CFO / Net profit
- 2.30
- Cash / Market cap
- 3.8%
- Cash per share
- ₹63.51
- Asset turnover
- 0.64
- Fixed asset turnover
- 1.93
- Capital intensity
- 0.52
- Debtor days
- 113 days
- Inventory turnover
- 2.70
- Cash conversion cycle
- 129 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹16 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹765 Cr |
| Sales | Operating profit | ₹225 Cr |
| Operating profit | Interest | ₹6 Cr |
| Operating profit | Depreciation | ₹24 Cr |
| Operating profit | Profit before tax | ₹195 Cr |
| Other income | Profit before tax | ₹18 Cr |
| Profit before tax | Tax and other | ₹54 Cr |
| Profit before tax | Net profit | ₹160 Cr |
Revenue and net profit
Revenue grew 43.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹341 Cr | ₹54 Cr |
| FY2022 | ₹520 Cr | ₹72 Cr |
| FY2023 | ₹617 Cr | ₹83 Cr |
| FY2024 | ₹688 Cr | ₹44 Cr |
| FY2025 | ₹990 Cr | ₹160 Cr |
Cash flows
FY2025: ₹116 Cr from operations, -₹118 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹27 Cr | -₹74 Cr |
| FY2022 | -₹10 Cr | -₹132 Cr |
| FY2023 | ₹56 Cr | ₹36 Cr |
| FY2024 | ₹101 Cr | -₹236 Cr |
| FY2025 | ₹116 Cr | -₹118 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹990 Cr+43.9%1Y
- Net profit
- ₹160 Cr+263.6%1Y
- Cash from operations
- ₹116 Cr
- Free cash flow
- -₹118 Cr
- Revenue CAGR, 5Y
- 23.4%
- EBITDA CAGR, 5Y
- 15.4%
- Net profit CAGR, 5Y
- 10.3%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹990 Cr | ₹225 Cr | — | ₹160 Cr | ₹116 Cr | -₹118 Cr | 12.2% | +43.9% | +263.6% |
Monthly returns
Month-by-month returns of ACUTAAS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹1,538 Cr |
| Equity capital | ₹41 Cr |
| Reserves | ₹1,271 Cr |
| Borrowings | ₹11 Cr |
| Other liabilities | ₹215 Cr |
| Assets | ₹1,538 Cr |
| Fixed assets | ₹499 Cr |
| Capital work in progress | ₹130 Cr |
| Investments | ₹70 Cr |
| Other assets | ₹839 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
ACUTAAS trades at 61.2x earnings against a peer median of 52.6x (a 16% premium).
Not shown (no positive earnings and no EV / Sales): JUBILANT PHARMOVA LIMITED.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| ACUTAAS CHEMICALS LIMITEDACUTAASthis companyP/E ↑ premium | ₹13,806 Cr | 61.2x | 9.7x | 6.5% | 154.5x |
| JUBILANT PHARMOVA LIMITEDJUBLPHARMA | ₹16,581 Cr | — | 7.4x | 1.3% | 140.4x |
| Dr. Agarwal's Health Care LimitedAGARWALEYE | ₹15,850 Cr | 302.0x | 8.1x | 2.0% | 62.8x |
| ALEMBIC PHARMACEUTICALS LIMITEDAPLLTD | ₹15,765 Cr | 35.5x | 3.0x | 13.6% | 15.2x |
| Natco Pharma Ltd.NATCOPHARM | ₹15,582 Cr | 10.3x | 1.9x | 23.4% | 8.8x |
| Granules India Ltd.GRANULES | ₹14,372 Cr | 39.7x | 4.0x | 14.0% | 18.5x |
| Caplin Point Laboratories Ltd.CAPLIPOINT | ₹13,763 Cr | 39.4x | 7.5x | — | — |
| Rainbow Children's Medicare LimitedRAINBOW | ₹12,756 Cr | 51.8x | 8.1x | 16.7% | 29.5x |
| RUBICON RESEARCH LIMITEDRUBICON | ₹11,141 Cr | 65.0x | — | 5.0% | 115.2x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
ACUTAAS since 1 January, against earlier years.
Historical volatility
ACUTAAS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 24.0% |
| FY2022 | 20.0% |
| FY2023 | 20.0% |
| FY2024 | 16.0% |
| FY2025 | 23.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹990 Cr |
| Costs | |
| Interest | ₹6 Cr |
| Expenses | ₹765 Cr |
| Operating profitOperating Profit | ₹225 Cr |
| Other income and charges | |
| Profit before tax | ₹214 Cr |
| Tax | |
| Net profitNet Profit | ₹160 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹1,538 Cr |
| Equity capitalEquity Capital | ₹41 Cr |
| Reserves | ₹1,271 Cr |
| Borrowings | ₹11 Cr |
| Other liabilitiesOther Liabilities | ₹215 Cr |
| AssetsTotal Assets | ₹1,538 Cr |
| Fixed assetsFixed Assets | ₹499 Cr |
| Capital work in progressCWIP | ₹130 Cr |
| Investments | ₹70 Cr |
| Other assetsOther Assets | ₹839 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹116 Cr |
| Investing cash flowCash from Investing Activity | -₹234 Cr |
| Financing cash flowCash from Financing Activity | ₹274 Cr |
| Change in cashNet Cash Flow | ₹155 Cr |
Learn while you research
Academy chapters picked for ACUTAAS CHEMICALS LIMITED and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 61.2, learn when high multiples are justified.6 min read
- 04 Growth Investing44% revenue growth is in the top tier, learn how to value growth.7 min read
- 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read